Lars Møller Pedersen

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations

Lymphoid Neoplasia, Oncology, Phase 3 +8

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma

Martin Hutchings, Annika Loft, Mads Hansen et al. · Blood · 2005 · 715 citations · Full text

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Tina Green, Ken H. Young, Carlo Visco et al. · Journal of Clinical Oncology · 2012 · 677 citations · Full text

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Bertrand Coiffier, Stéphane Leprêtre, Lars Møller Pedersen et al. · Blood · 2007 · 383 citations

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, John F. Seymour, Pierre Feugier et al. · Journal of Clinical Oncology · 2019 · 266 citations · Full text